Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Date:12/10/2007

Dr. Paul Richardson presents Phase 1 results demonstrating clinical

activity of perifosine in combination with bortezomib in patients previously treated with bortezomib, and provides an update on an ongoing

Phase 2 study of perifosine in combination with dexamethasone

NEW YORK, Dec. 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that positive phase 1 & phase 2 data of perifosine (KRX-0401) in patients with advanced, relapsed/refractory multiple myeloma (MM) were presented on Saturday, December 8, 2007 at the 49th Annual Meeting of the American Society of Hematology. In two separate poster presentations, Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute (DFCI) in Boston, MA, provided the phase 1 results on the clinical activity of perifosine in combination with Bortezomib, and an update on an ongoing phase 2 study of perifosine in combination with dexamethasone.

Phase 1 Perifosine + VELCADE(R) (Vel)

Poster 324-I: A MULTICENTER PHASE 1/2 TRIAL OF PERIFOSINE (KRX-0401) + BORTEZOMIB IN RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS PREVIOUSLY TREATED WITH BORTEZOMIB: PHASE I RESULTS

Eighteen patients (median age 64 yrs) with advanced MM (83% relapsed and refractory) were enrolled in one of four cohorts. Patients had a median of 5 lines of prior therapy and 100% of patients were previously treated with at least one course of therapy on bortezomib. Perifosine was escalated from 50 to 100 mg qd while bortezomib was escalated from 1.0 to 1.3 mg/mm2. No dose- limiting toxicity and no grade 3 peripheral neuropathy were reported. Toxicities were generally well
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...gnostic Value of Circulating Tumor Cells, RARITAN...prospective,clinical trial found the number of cir...of progression-free and overall survival among met... report published in the July 1,issue of the Journ... the US, the Netherlands, and the United,Kingdom, ...
(Date:7/24/2008)... 24 /PRNewswire-USNewswire/ -- Headlines claiming ...hole story. The small scale,preliminary study tha...production, is based on recollected intake of soyf.... "This study is confounded by many,issues, thus I...al of,caution," warned Dr. Tammy Hedlund, a resear...
(Date:7/23/2008)...st Approved Systemic Therapy to Treat the Disease ...RNewswire-FirstCall/ --,Bayer HealthCare Pharmaceu...X) today announced that The New England Journal of...onstrating that Nexavar(R) (sorafenib),tablets dec... patients with,unresectable hepatocellular carcino...
(Date:7/23/2008)... Some Areas of the Body Have Greater Concentration... /PRNewswire-USNewswire/ -- Fat removed,from the l...as found to be,an excellent source of stem cells, ...eas of the body, reports a Brazilian-based study i...the official medical journal of the,American Socie...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Soyfoods Do Not Impact Sperm Count 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Data Show Common Allergy Tests Are Not Interchangeable 18816 1Data Show Common Allergy Tests Are Not Interchangeable 18816 2Data Show Common Allergy Tests Are Not Interchangeable 18816 3Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 1Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 2Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 3Angiotech to participate in Bank of America Health Care Conference 5229 1Federal polar bear research critically flawed says study in INFORMS journal 3237 1Federal polar bear research critically flawed says study in INFORMS journal 3237 2
... Risk of Late Thrombosis is Minimized with Genous ... -- The efficacy of,OrbusNeich,s Genous(TM) Bio-en...g-eluting stents, while the risk of late thrombosi... an interim,analysis of post-marketing data presen...roPCR 2007 in Barcelona, Spain. , Collected from m...
... PRINCETON, N.J.--(BUSINESS WIRE)--May 23, 2007 - ...the publication of a,review validating the utility...unction of the WW domain-containing oxidoreductase...nown involvement,in breast, prostate, lung, pancre...viewed article was published in the online,edition...
Other Medicine Technology:Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 2Efficacy of OrbusNeich's Genous Bio-Engineered R Stent Compares,Favorably to Drug-Eluting Stents 3Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 2Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 3Cytogen Reports Publication Validating the Utility of its,Proprietary ProChart Database 4
(Date:7/25/2008)..., N.Y., July 25 /PRNewswire-USNewswire/ -- Anthony...ality Officer and Vice President,of Strategic Plan...und, a,national foundation committed to improving ...the foundation,s Program on Health Care Quality,Im...scom.com/cgi-bin/prnh/20080725/DC28791LOGO ), Bo...
(Date:7/25/2008)...leaning products reduces lung function, increases ..., July 25 (HealthDay News) -- A clean, fresh-smell...nding on what type of cleaning and air freshening ...at exposure to cleaning products or air fresheners...(VOC) called 1,4 dicholorobenzene (1,4 DCB), can r...
(Date:7/25/2008)... Though the number of jobs created in the...anies reported a different kind of slowdown: they ...ths. , Seattle, WA (PRWEB...ed in the medical field slowed in June overall, ph...f slowdown that will be music to the ears of sales...
(Date:7/25/2008)... Corporation Executive, Robert J. Reilly, Joins Ae...thon Inc.,( http://www.aethon.com ), the leading d...ain logistics, today announced that Robert J. Reil... -- Chief Financial Officer., Reilly, who was mos...cKesson Corporation,s Specialty Pharmacy Division,...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Aethon, Inc. Names New Chief Financial Officer 2
...h world but the death rate from it is falling due ...ers from the University of Southern Denmark carrie...0,000 people between 1993 and 1999. While the prop... by around three percent annually during the six-y...
...it suicide than other people, scientists said on F...s of more than 20,000 same-sex twins who died betw...ide with the wider population. They found that the...ardless of their sex.// The findings came as a sur...
...ck, the most important thing they can do to increa...to their heart is to get help as soon as possible....tional Heart, Lung, and Blood Institute, many peop...y experience heart attack symptoms because they do...
...hown to boost vitamin D levels and now researchers...r sun exposure during childhood and early adolesce...sclerosis, according to the study. Australian inve...which is located at high latitude and has a high p...
Other Medicine News:Health News:Recognize Heart Attack Signs 2
...Ovulation Predicting Test is a qualitative immunoa...e (hLH) in human urine to predict the occurrence o...on of human luteinizing hormone (hLH). Usually, ar...rief, significant rapid increase called the "LH su...
The Shandon Cryotome SME Cryostat model is a sophisticated, top of the line cryostat that combines automated electronic advance and hands-free sectioning with fully independent specimen temperature c
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning.
The Shandon Varistain Gemini is designed for high throughput, precision, safety, durability and ultimate flexibility in histology and cytology staining applications. It features load-on-demand multip
Medicine Products: